|
1
|
Lee C, Collichio F, Ollila D and Moschos
S: Historical review of melanoma treatment and outcomes. Clin
Dermatol. 31:141–147. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chien AJ, Moore EC, Lonsdorf AS,
Kulikauskas RM, Rothberg BG, Berger AJ, Major MB, Hwang ST, Rimm DL
and Moon RT: Activated Wnt/beta-catenin signaling in melanoma is
associated with decreased proliferation in patient tumors and a
murine melanoma model. Proc Natl Acad Sci USA. 106:1193–1198. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cui C, Mao L, Chi Z, Si L, Sheng X, Kong
Y, Li S, Lian B, Gu K, Tao M, et al: A phase II, randomized,
double-blind, placebo-controlled multicenter trial of Endostar in
patients with metastatic melanoma. Mol Ther. 21:1456–1463. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sullivan R, LoRusso P, Boerner S and
Dummer R: Achievements and challenges of molecular targeted therapy
in melanoma. Am Soc Clin Oncol Educ Book. 2015.177–186. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Atanasov AG, Waltenberger B,
Pferschy-Wenzig EM, Linder T, Wawrosch C, Uhrin P, Temml V, Wang L,
Schwaiger S, Heiss EH, et al: Discovery and resupply of
pharmacologically active plant-derived natural products: A review.
Biotechnol Adv. 33:1582–1614. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Harvey AL, Edrada-Ebel R and Quinn RJ: The
re-emergence of natural products for drug discovery in the genomics
era. Nat Rev Drug discov. 14:111–129. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Goncalves LM, Valente IM and Rodrigues JA:
An overview on cardamonin. J Med Food. 17:633–640. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li Y, Qin Y, Yang C, Zhang H, Li Y, Wu B,
Huang J, Zhou X, Huang B, Yang K and Wu G: Cardamonin induces
ROS-mediated G2/M phase arrest and apoptosis through inhibition of
NF-κB pathway in nasopharyngeal carcinoma. Cell Death Dis.
8:e30242017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang J, Sikka S, Siveen KS, Lee JH, Um
JY, Kumar AP, Chinnathambi A, Alharbi SA, Basappa, Rangappa KS, et
al: Cardamonin represses proliferation, invasion, and causes
apoptosis through the modulation of signal transducer and activator
of transcription 3 pathway in prostate cancer. Apoptosis.
22:158–168. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wu N, Liu J, Zhao X, Yan Z, Jiang B, Wang
L, Cao S, Shi D and Lin X: Cardamonin induces apoptosis by
suppressing STAT3 signaling pathway in glioblastoma stem cells.
Tumour Biol. 36:9667–9676. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Niu P, Shi D, Zhang S, Zhu Y and Zhou J:
Cardamonin enhances the anti-proliferative effect of cisplatin on
ovarian cancer. Oncol Lett. 15:3991–3997. 2018.PubMed/NCBI
|
|
12
|
Elmore S: Apoptosis: A review of
programmed cell death. Toxicol Pathol. 35:495–516. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rosen LS, Lorusso P, MA WW, Goldman JW,
Weise A, Colevas AD, Adjei A, Yazji S, Shen A, Johnston S, et al: A
first-in-human phase I study to evaluate the MEK1/2 inhibitor,
cobimetinib, administered daily in patients with advanced solid
tumors. Invest New Drugs. 34:604–613. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Park MK, Lee HJ, Choi JK, Kim HJ, Kang JH,
Lee EJ, Kim YR, Kang JH, Yoo JK, Cho HY, et al: Novel
anti-nociceptive effects of cardamonin via blocking expression of
cyclooxygenase-2 and transglutaminase-2. Pharmacol Biochemistry
Behav. 118:10–15. 2014. View Article : Google Scholar
|
|
16
|
Larkin J, Chiarion-Sileni V, Gonzalez R,
Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M,
Rutkowski P, et al: Combined nivolumab and ipilimumab or
monotherapy in untreated melanoma. N Engl J Med. 373:23–34. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Caroline R, Jacob S, Georgina VL, Ana A,
Jean JG, Laurent M, Adil D, Matteo SC, Catriona M, Michal L, et al:
Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med.
372:2521–2532. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Caroline R, Georgina VL, Jacob S, Ana A,
Jean JG, Laurent M, Adil D, Matteo SC, Catriona M, Michal L, et al:
Long-term outcomes in patients (pts) with ipilimumab (ipi)-naïve
advanced melanoma in the phase 3 KEYNOTE-006 study who completed
pembrolizumab (pembro) treatment. J Clin Oncol. 15 (Suppl):S35.
2017.
|
|
19
|
Wang S, Zhai C, Zhang Y, Yu Y, Zhang Y, Ma
L, Li S and Qiao Y: Cardamonin, a novel antagonist of hTRPA1 cation
channel, reveals therapeutic mechanism of pathological pain.
Molecules. 21:E11452016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu L, Chen X and Hu Z: Separation and
determination of alpinetin and cardamonin in alpinia katsumadai
hayata by flow injection-micellar electrokinetic chromatography.
Talanta. 71:155–159. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fulda S, Gorman AM, Hori O and Samali A:
Cellular stress responses: Cell survival and cell death. Int J Cell
Biol. 2010:2140742010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chan SL and Yu VC: Proteins of the bcl-2
family in apoptosis signalling: From mechanistic insights to
therapeutic opportunities. Clin Exp Pharmacol Physiol. 31:119–128.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hata AN, Engelman JA and Faber AC: The
BCL2 family: Key mediators of the apoptotic response to targeted
anticancer therapeutics. Cancer Discov. 5:475–487. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhu Y, Wen X and Zhao P: MicroRNA-365
inhibits cell growth and promotes apoptosis in melanoma by
targeting BCL2 and cyclin D1 (CCND1). Med Sci Monit. 24:3679–3692.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Radha G and Raghavan SC: BCL2: A promising
cancer therapeutic target. Biochim Biophys Acta Rev Cancer.
1868:309–314. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Monie TP and Bryant CE: Caspase-8
functions as a key mediator of inflammation and pro-IL-1β
processing via both canonical and non-canonical pathways. Immunol
Rev. 265:181–193. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li J and Yuan J: Caspases in apoptosis and
beyond. Oncogene. 27:6194–6206. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Break MKB, Hossan MS, Khoo Y, Qazzaz ME,
Al-Hayali MZK, Chow SC, Wiart C, Bradshaw TD, Collins H and Khoo
TJ: Discovery of a highly active anticancer analogue of cardamonin
that acts as an inducer of caspase-dependent apoptosis and
modulator of the mTOR pathway. Fitoterapia. 125:161–173. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ma L, Xu Y, Wei Z, Xin G, Xing Z, Niu H
and Huang W: Deoxyarbutin displays antitumour activity against
melanoma in vitro and in vivo through a p38-mediated mitochondria
associated apoptotic pathway. Sci Rep. 7:71972017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bush JA, Cheung KJ Jr and LI G: Curcumin
induces apoptosis in human melanoma cells through a Fas
receptor/caspase-8 pathway independent of p53. Exp Cell Res.
271:305–314. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kaltschmidt B, Greiner JFW, Kadhim HM and
Kaltschmidt C: Subunit-specific role of NF-κB in cancer.
Biomedicines. 6:E442018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Turillazzi E, Neri M, Cerretani D,
Cantatore S, Frati P, Moltoni L, Busardò FP, Pomara C, Riezzo I and
Fineschi V: Lipid peroxidation and apoptotic response in rat brain
areas induced by long-term administration of nandrolone: The mutual
crosstalk between ROS and NF-kB. J Cell Mol Med. 20:601–612. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang D and Liu P: Ingenol-3-Angelate
suppresses growth of melanoma cells and skin tumor development by
downregulation of NF-κB-cox2 signaling. Med Sci Monit. 24:486–502.
2018. View Article : Google Scholar : PubMed/NCBI
|
